Alliance for Pandemic Preparedness

February 3, 2021

Neutralization of SARS-CoV-2 VOC 501Y.V2 by Human Antisera Elicited by Both Inactivated BBIBP-CorV and Recombinant Dimeric RBD ZF2001 Vaccines

Category:

Topic:

Keywords (Tags): , ,

[Pre-print, not peer-reviewed] Sera from 12 participants who received either the inactivated virus vaccine BBIP-CorV or the ZF2001 RBD protein subunit vaccine (both manufactured in China) showed neutralizing activity against the 501Y.V2 SARS-CoV-2 variant (first identified in South Africa). Neutralization was measured by microcytopathogenic effect assay and there were slightly reduced geometric mean antibody titers (about 1.6-fold for each vaccine) in the sera from participants vaccinated with either vaccine compared to those against the wild type D614G strain.

Huang et al. (Feb 2, 2021). Neutralization of SARS-CoV-2 VOC 501Y.V2 by Human Antisera Elicited by Both Inactivated BBIBP-CorV and Recombinant Dimeric RBD ZF2001 Vaccines. BioRxiv. https://doi.org/10.1101/2021.02.01.429069